Recent Advances in Preventing Neurodegenerative Diseases

Abstract

The worldwide healthcare burden of neurodegenerative diseases is on the rise—a crisis created through a combination of increased caseload and lack of effective treatments. The limitations of pharmacotherapy in these disorders have led to an urgent shift toward research and clinical trials for the development of novel compounds, interventions, and methods that target shared features across the spectrum of neurodegenerative diseases. 

Neurodegenerative diseases refer to a class of diseases with a high incidence rate caused by the degeneration and death of nerve cells, including Alzheimer's disease and Parkinson's disease. These disorders take a toll on the patient's physical health and lead to a loss of self, social, work, and family life. At the same time, they also have a serious impact on the patient's memory.

However, we cannot deny the importance of memory because of this. Memory is an important part of human intelligence and an important basis for our study, work, and life. It serves as a bridge between the past, present, and future, allowing us to learn from our mistakes, gain experience, and reason about future outcomes. Therefore, we should actively take measures to protect and improve our memory.

First of all, we should promote and protect memory through a regular lifestyle. Getting enough sleep and sticking to a regular diet can improve our brain function and focus, which in turn can help strengthen our memory. In addition, maintaining a positive mood and exercising can also improve brain function, increasing mental flexibility and creativity.

Secondly, we can use various methods to help us remember, such as writing notes, reviewing repeatedly, creating associations and using memory techniques, and so on. These techniques can help us retain information faster and make memories more durable and organized. In addition, we can use tools such as memory games to train and improve memory.

Finally, we should not be discouraged when we are confronted with inescapable problems such as neurodegenerative diseases. When we actively take steps to maintain our health and preserve our memory, we can delay or slow the progression of the disease as much as possible. And, we can also believe that modern medicine and science and technology are constantly making breakthroughs, providing us with better treatment and rehabilitation programs, so that we can better deal with these problems.

In conclusion, the emergence of neurodegenerative diseases does have a serious impact on our memory. However, we cannot deny the importance of memory. Instead, we should actively take steps to protect and improve our memory. When we face unavoidable problems such as diseases, we should not lose confidence and believe that modern medicine and technology will provide us with better support and help. From this point of view, we need to improve our memory. Cistanche can significantly improve memory because meat paste is a traditional Chinese medicinal material with many unique effects, one of which is to improve memory. The efficacy of minced meat comes from a variety of active ingredients it contains, including carboxylic acid, polysaccharides, flavonoids, etc. These ingredients can promote brain health through various channels.

Click know 10 ways to improve memory

Research targets include neuronal cell death, mitochondrial dysfunction, protein aggregation, and neuroinflammation. In the past few years, there has been a growth in understanding of the pathophysiologic mechanisms of neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington’s disease. This increase in knowledge has led to the discovery of numerous novel neuroprotective therapeutic targets. In this context, we reviewed and summarized recent advancements in neuroprotective strategies in neurodegenerative diseases.

Peer Review

The peer reviewers who approve this article are:

1. Yingfei Wang, Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA; Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA Competing interests: No competing interests were disclosed.

2. P Hemachandra Reddy, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Neuroscience & Pharmacology, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Neurology, Departments of School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Public Health Department of Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Department of Speech, Language and Hearing Sciences, School Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Competing interests: No competing interests were disclosed.

Introduction

Neurodegenerative diseases include a broad range of disorders characterized by neuronal injury or degeneration leading to neurological impairment. These diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD) that manifest in millions of people worldwide every year. The common characteristic of these disorders is neuronal loss or impairment resulting in chronic deterioration in memory, locomotor difficulties, psychological impairment, and cognitive defects. Researchers are pursuing a collaborative approach to preserve the function and networks of neural tissues before damage occurs. This neuroprotective approach focuses on the development of strategies that prevent or arrest various types of neuronal cell death mechanisms such as oxidative stress, mitochondrial dysfunction, neuroinflammation, protein aggregation, and defective autophagy, thus limiting disease progression. The purpose of this review is to summarize recent developments in neuroprotective strategies for neurodegenerative diseases.

Prevention of cell-autonomous neurodegeneration

Cells employ a variety of self-repair mechanisms to maintain and restore physiological homeostasis. When a cell exceeds the ability to overcome stress or damage, intracellular homeostasis collapses and induces a series of cell death signaling cascades. Over the last few years, studies have shown that apoptotic cell death is not the only pathway dominating neuronal loss in neurodegenerative diseases. Among them, poly (ADP-ribose) (PAR)-dependent cell death, or parthanatos, has been established as being responsible for neuronal loss in a variety of neurological diseases, including AD, PD, ALS, and HD1. PARP1 plays a multi-functional role in a variety of cellular processes such as DNA repair pathways, genomic stability, and inflammation2. Oxidative stress or nitric oxide production damages DNA, resulting in excessive intracellular PAR accumulation due to PARP1 activation1. Several cellular processes result in parthanatos, including PARP1 overactivation, the release of apoptosis-inducing factor (AIF) from mitochondria, and co-translocation of AIF and macrophage migration inhibitory factor (MIF) into the nucleus, leading to DNA fragmentation and cell death2–4.

Overactivation of PARP1 and PAR accumulation has been observed in the brains of AD patients and mouse models5,6, and genetic or pharmacological inhibition of PARP1-protected neurons in AD models7–9. Recent studies have also indicated that cells of cognitively impaired patients are more susceptible to H2 O2 -induced parthanatos10, tissue acidosis-induced amplification of neuronal parthanatos11, and robust internal inflammation response following ischemic injuries12,13. Moreover, amyloid β (Aβ) causes hippocampal neurotoxicity by inducing oxidative stress–mediated PARP1 activation, which leads to transient receptor potential melastatin-related 2 (TRPM2) activation and Ca2+ influx and mitochondrial dysfunction14. Notably, studies have shown that neurons are protected by PARP1 inhibition, which implies that PARP1 inhibition may have therapeutic value for the treatment of AD.

Recent discoveries in PD models show more direct evidence that parthanatos is the main cell death pathway in pathologic α-synuclein neurodegeneration. In this pathway, PAR is a key mediator, promoting α-synuclein toxicity and fibril transmission, exacerbating neurotoxicity in a feed-forward loop15. Interaction between PAR and α-synuclein was also found in the post-mortem brains of patients with PD16–18. In addition, inhibition of PARP1 may promote α-synuclein autophagy via transcription factor EB-mediated signaling and downregulation of mammalian target of rapamycin (mTOR) signaling, which lessened cytotoxicity of α-synuclein aggregation17. Genetic depletion of PARP1 and oral administration of PARP1 inhibitor prevented neurodegeneration and improved motor ability in both sporadic and genetic mouse models of PD15,17. Moreover, PAR levels were increased in the cerebral spinal fluid and brains of patients with PD15, suggesting that PARP1 could be a theragnostic biomarker and a disease-modifying therapeutic target in PD19.

In the ALS brain, expression of PARP1 is increased and localized to a subset of TAR DNA-binding protein 43 (TDP43) inclusions, primary cytological features of ALS20,21. Additionally, PAR favors the accumulation and aggregation of hnRNP A1 and TDP43 in stress granules, as observed in patients with ALS22,23. Elevated PARP activity is observed in the motor neurons of the ALS spinal cord, and inhibition of PARP mitigates hnRNP A1- or TDP43-mediated neurotoxicity in cell and drosophila models of ALS22,24.

In HD, elongated polyglutamine (polyQ) is responsible for huntingtin (htt) protein aggregation and is associated with neuronal inclusions and toxicity25. Recently, several co-morbid pathogenic processes were identified in the caudate nucleus of HD brains. The accumulation of damaged DNA increased PARP1 expression, and localization of the protein to the DNA damage site was found in conjunction with only weak caspase 3 activation26. This finding suggests a pathologic relationship between caspase-independent parthanatos and HD. Moreover, the treatment of PARP1 inhibitor to HD model R6/2 mutant mice showed longer survival and less neuropathologic dysfunction27,28. Although these findings suggest a neuroprotective effect of PARP1 in HD, further studies are required to determine the direct relationship of parthanatos to HD.

Dysregulation of PARP1 activation and increased PAR levels contribute to the pathogenesis of various neurodegenerative diseases by promoting protein aggregation and parthanatos. Thus, neuroprotective strategies aimed to inhibit PARP1 activation may have therapeutic potential in those disorders. Many well-characterized PARP inhibitors in clinical use have yet to be tested for use in neurodegenerative disease29. These should be considered for neuroprotective treatment for neurological diseases.

Prevention of non-cell-autonomous neurodegeneration

Glial cells play a central role in neuronal support by maintaining homeostasis, nutrient transportation, and neurogenesis in healthy brains30. Importantly, a growing body of research has shown that dysfunctional non-neuronal cells such as microglia and astrocytes directly contribute to neurodegeneration and cell death (so-called non-cell-autonomous neurodegeneration) in a variety of neurodegenerative diseases.

In the brain, microglia are the resident macrophages and primary immune cells. Therefore, they play an important role in neuronal disease. Recent single-cell RNA analysis of central nervous system (CNS) immune cells in AD models discovered a pro-inflammatory signature present in Aβ plaque-associated microglia, also known as disease-associated microglia (DAM), which might play both a toxic and a protective role in AD31–34. DAMs have also been observed in other neurodegenerative conditions, including aging, ALS, and frontotemporal dementia (FTD)33. Reactive microglia are presented in post-mortem AD brains and have been shown to promote synaptic loss and neuroinflammation in AD35,36. 

Emerging studies suggest that dysregulation of neuroinflammation is modulated by TREM2 and ApoE, which eventually contribute to synaptic loss in multiple AD models33,37–40. Additionally, inefficient microglia clearance of pathologic proteins plays an adverse role in the spread of tau in tauopathy and AD41. Polarization of microglia toward a neuroprotective M2 type improves neurological deficits in post-ischemic stroke through activation of AMP-activated protein kinase (AMPK) and nuclear factor erythroid 2-related factor 2 (Nrf2) or peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) neuroprotective pathways42,43. Many PD-related genes, including α-synuclein, PINK1, and parkin, are expressed in glial cells. Mutated gene products are involved in microglial dysfunction during PD pathogenesis44. Also, microglia have been found to modulate the transmission of α-synuclein in the brain45,46. Recent spatial transcriptomics of ALS patients and mouse models revealed that changes in microglial gene expression preceded and contributed to motor neuron loss 47. 

Accordingly, pharmacological blockage of neuregulin (NRG) receptors present on microglia (associated with ALS disease progression) has been shown to slow disease advancement in a SOD1-ALS mouse model 48. In summary, microglia are thought to have both beneficial and detrimental functions in neurodegenerative diseases. Thus, induction of DAM or homeostatic microglia signature and subsequent prevention of neurotoxic microglia signature could be promising therapeutic strategies for neuroprotection in neurodegenerative diseases, but the factors associated with heterogenous microglial phenotype will need to be defined in more detail.

Astrocytes are the most abundant population of glial cells in the CNS and perform a broad range of homeostatic functions. Consequently, it is not surprising that the loss of normal astrocyte function is involved in the pathogenesis of neurodegenerative diseases. A 2017 study showed that activated microglia induce the formation of neurotoxic reactive astrocytes by secreting interleukin 1α (IL-1α), tumor necrosis factor α (TNF-α), and C1q49. These reactive astrocytes were found in post-mortem brains of human neurodegenerative diseases, including AD, PD, ALS, and HD49. The contribution of reactive astrocytes to neurodegeneration has been determined in disease models of PD50, AD51, ALS52, and MS53. The presence of reactive astrocytes in numerous disease models creates a prime opportunity for the development of neuroprotective therapies that can be shared across multiple neurodegenerative diseases. For example, direct prevention of microglia-mediated naïve astrocyte transformation into reactive astrocytes by Glucagon-like peptide 1 (GLP1) receptor agonist improves behavioral deficits and neurodegeneration in pathologic α-synuclein mouse models of PD50. 

This restorative intervention could be applied to other neurodegenerative disease models. GLP1 receptor agonists are protective in AD mouse models54. Additionally, in mouse models for PD, activation of receptor CD44 (expressed on astrocytes) helped reduce nuclear factor kappa B (NFκB) activation and inflammatory response55. In another study, dopaminergic neurons produced high levels of prokineticin 2 (PK2) protein56. Astrocytes have PK2 receptors; upon ligand-receptor binding, there is a reduction in pro-inflammatory factors and an increase in several antioxidant genes56. Genetic depletion of reactive astrocytes markedly extended survival in ALS mouse models57.
Inhibition of astrocyte reactivity by modulating the JAK2-STAT3 pathway reduced amyloid deposition and synaptic and behavioral deficits in an AD mouse model 58. In ischemic stroke mouse models, knockout of glutamate-releasing SWELL1 channel present in astrocytes decreased excitotoxicity59. More recently, however, it has been identified that the phenotype diversity of astrocytes is observed in brains of neurodegenerative diseases and extends beyond the A1 and A2 phenotypes60–65. Thus, further investigation is needed to better understand the molecular mechanisms of reactive astrocytes and their specific role within different neurodegenerative pathologies, especially how neurotoxic signals transduce and are shared across multiple neurodegenerative conditions.

Conclusions

Neurodegenerative diseases are the result of several factors, including genetic mutations, neuronal cell death, mitochondrial dysfunction, protein aggregation, flawed protein recycling, and innate immune responses due to activation in glial cells. Thus, neuroprotection from cell-autonomous neurodegeneration could be achieved by directly targeting degenerating neurons and from non-cell-autonomous neurodegeneration by targeting their neighboring glial cells (Figure 1). Thus, a multifaceted approach targeting both cell-autonomous and non-cell-autonomous mechanisms may be required to prevent or slow neurodegeneration. During the previous decade, consistent and focused studies have revealed the causal factors in neurodegenerative diseases. Understanding the molecular mechanisms of neurodegeneration is an essential step forward in the development of novel neuroprotective therapies. The last couple of years have seen advancements in both research and clinical understanding of potential novel neuroprotective therapeutics. Owing to the tremendous effort, these therapies have progressed beyond the lab and into the clinical testing stage. Despite this progress, therapies to prevent or decrease disease progression and restore neuronal function remain a challenge and an ongoing focus in both research and clinical practice. Thus, further investigation into the neurodegenerative pathways and the identification and development of neuroprotective agents are needed to develop promising disease-modifying therapeutic approaches for the treatment of neurodegenerative disease.

Acknowledgments

The authors acknowledge the joint participation by the Adrienne Helis Malvin Medical Research Foundation and the Diana Helis Henry Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with the Johns Hopkins Hospital and the Johns Hopkins University School of Medicine and the Foundation’s Parkinson’s Disease Programs M-2017, H-2018, and M-2019. We thank Noelle Burgess (Johns Hopkins University) for assistance with the illustrations in Figure 1.

References

Park H, Kam TI, Dawson TM, et al.: Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. Int Rev Cell Mol Biol. 2020; 353: 1–29. PubMed Abstract | Publisher Full Text 

2. Wang Y, Kim NS, Haince JF, et al.: Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011; 4(167): ra20. PubMed Abstract | Publisher Full Text | Free Full Text 

3. Wang Y, An R, Umanah GK, et al.: A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science. 2016; 354(6308): aad6872. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation 

4. Wang Y, Kim NS, Li X, et al.: Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos). J Neurochem. 2009; 110(2): 687–96. PubMed Abstract | Publisher Full Text | Free Full Text 

5. Love S, Barber R, Wilcock GK: Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer’s disease. Brain. 1999; 122(Pt 2): 247–53. PubMed Abstract | Publisher Full Text 

6. Martire S, Fuso A, Rotili D, et al.: PARP-1 modulates amyloid-beta peptide-induced neuronal damage. PLoS One. 2013; 8(9): e72169. PubMed Abstract | Publisher Full Text | Free Full Text 

7. Abeti R, Abramov AY, Duchen MR: Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain. 2011; 134(Pt 6): 1658–72. PubMed Abstract | Publisher Full Text 

8. Kauppinen TM, Suh SW, Higashi Y, et al.: Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β. J Neuroinflammation. 2011; 8: 152. PubMed Abstract | Publisher Full Text | Free Full Text 

9. Turunc Bayrakdar E, Uyanikgil Y, Kanit L, et al.: Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1-42)- induced rat model of Alzheimer’s disease. Free Radic Res. 2014; 48(2): 146–58. PubMed Abstract | Publisher Full Text 

10. Salech F, Ponce DP, SanMartín CD, et al.: PARP-1 and p53 Regulate the Increased Susceptibility to Oxidative Death of Lymphocytes from MCI and AD Patients. Front Aging Neurosci. 2017; 9: 310. PubMed Abstract | Publisher Full Text | Free Full Text 

11. Zhang J, Li X, Kwansa H, et al.: Augmentation of poly(ADP-ribose) polymerase dependent neuronal cell death by acidosis. J Cereb Blood Flow Metab. 2017; 37(6): 1982–93. PubMed Abstract | Publisher Full Text | Free Full Text 

12. Jang HR, Lee K, Jeon J, et al.: Poly (ADP-Ribose) Polymerase Inhibitor Treatment as a Novel Therapy Attenuating Renal Ischemia-Reperfusion Injury. Front Immunol. 2020; 11: 564288. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation 

13. Li X, Ling Y, Cao Z, et al.: Targeting intestinal epithelial cell-programmed necrosis alleviates tissue injury after intestinal ischemia/reperfusion in rats. J Surg Res. 2018; 225: 108–17. PubMed Abstract | Publisher Full Text 

14. Li X, Jiang LH: Multiple molecular mechanisms form a positive feedback loop driving amyloid β42 peptide-induced neurotoxicity via activation of the TRPM2 channel in hippocampal neurons. Cell Death Dis. 2018; 9(2): 195. PubMed Abstract | Publisher Full Text | Free Full Text 

15. Kam TI, Mao X, Park H, et al.: Poly(ADP-ribose) drives pathologic αsynuclein neurodegeneration in Parkinson’s disease. Science. 2018; 362(6414): eaat8407.

For more information:1950477648nn@gamil.com